The src homology 2 (SH2) domain-containing protein tyrosine phosphatase SHP-2 has been implicated as an important positive regulator of several mitogenic signaling pathways. SHP-2 has more recently been shown to be tyrosine phosphorylated and recruited to the gp130/LIFR subunits of the CNTF receptor complex upon stimulation with ciliary neurotrophic factor (CNTF). CNTF does not, however, have a proliferative effect on responsive cells, but rather enhances the survival and differentiation of sympathetic, motor, and sensory neurons. In the Preliminary Studies section the applicants demonstrate that expression of an interfering SH2 domain mutant of SHP-2 in a neuroblastoma cell line increases CNTF induction of a vasoactive intestinal peptide (VIP) reporter gene and in cultures of sympathetic neurons results in an upregulation of endogenous VIP, substance P (SP) and choline acetyltransferase (ChAT) gene expression. They also found in parallel studies that expression of the SHP-2 interfering mutant abolishes CNTF induction of c-Fos protein levels. Members of the CNTF family of cytokines transmit their signal by activating signaling pathways involving both STAT and Fos-Jun (AP-1) transcription factors and activated STAT is necessary for induction of the VIP gene. Taken together, these data indicate that SHP-2 has dual and opposing roles in a signaling cascade triggered by the same ligand, as illustrated by its negative function in induction of VIP, SP and ChAT levels and positive function in induction of c-Fos levels. In this proposal they will examine in detail the pathways that are activated by neurocytokines such as CNTF and define the molecular mechanisms of how SHP-2 regulates these parallel signaling pathways.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS035996-04
Application #
6393862
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Program Officer
Mamounas, Laura
Project Start
1998-07-24
Project End
2003-01-31
Budget Start
2001-07-01
Budget End
2003-01-31
Support Year
4
Fiscal Year
2001
Total Cost
$201,647
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Xiang, Zhongmin; Valenza, Marta; Cui, Libin et al. (2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 ? contributes to dysmyelination in experimental models of Huntington's disease. J Neurosci 31:9544-53
Xiang, Zhongmin; Reeves, Steven A (2009) Simvastatin induces cell death in a mouse cerebellar slice culture (CSC) model of developmental myelination. Exp Neurol 215:41-7
Lin, Tong; Xiang, Zhongmin; Cui, Libin et al. (2006) New mouse oligodendrocyte precursor (mOP) cells for studies on oligodendrocyte maturation and function. J Neurosci Methods 157:187-94
Xiang, Zhongmin; Nesterov, Evgueni E; Skoch, Jesse et al. (2005) Detection of myelination using a novel histological probe. J Histochem Cytochem 53:1511-6
Mitsuhashi, T; Aoki, Y; Eksioglu, Y Z et al. (2001) Overexpression of p27Kip1 lengthens the G1 phase in a mouse model that targets inducible gene expression to central nervous system progenitor cells. Proc Natl Acad Sci U S A 98:6435-40
Yokogami, K; Wakisaka, S; Avruch, J et al. (2000) Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10:47-50
Aoki, Y; Huang, Z; Thomas, S S et al. (2000) Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. FASEB J 14:1965-73